Long COVID linked to persistent inflammation, study shows

Credit: Unsplash+.

Researchers from the University of Cambridge have made a breakthrough in understanding long COVID, a condition that continues to affect millions worldwide, presenting a significant challenge to global health systems.

Their study, published in Science Advances, sheds light on a potential biomarker for long COVID fatigue: the antiviral protein interferon gamma (IFN-γ).

This discovery not only offers hope for new treatments but also provides crucial insights that could be vital in the face of future coronavirus pandemics.

Long COVID’s most common and debilitating symptom, fatigue, has puzzled doctors and scientists since the pandemic began.

The Cambridge-led study embarked on a journey to unravel why some patients recover from long COVID while others do not, focusing on the role of IFN-γ in the disease’s persistence.

The Persistent Response of IFN-γ

Following an initial SARS-CoV-2 infection, the body naturally produces IFN-γ as part of its immune defense, typically ceasing once the infection clears. However, the study found that in some long COVID patients, high levels of IFN-γ continued for up to 31 months.

This persistence of IFN-γ production suggests an underlying immunological mechanism in long COVID, making IFN-γ a potential biomarker for the condition.

Dr. Benjamin Krishna, a co-author of the study, highlighted the significance of this finding, expressing hope that it could lead to the development of effective therapies and provide a solid diagnosis for patients.

The study was initiated by Dr. Nyarie Sithole, who established a long COVID clinic at Cambridge’s Addenbrooke’s Hospital and, along with Dr. Krishna and Dr. Mark Wills, began an in-depth study of the immunology of long COVID patients.

Understanding the Immunological Mechanism

The research involved analyzing blood samples from 111 COVID-confirmed patients, focusing on the presence of cytokines, small proteins essential to immune system functioning.

They discovered that white blood cells in individuals infected with SARS-CoV-2 produced IFN-γ, and this production persisted in long COVID patients. The team identified CD8+ T cells, in contact with CD14+ monocytes, as the precise cell types responsible for producing IFN-γ.

This link between IFN-γ and long COVID symptoms, such as fatigue, muscle ache, and depression, underscores the protein’s role in the condition’s severity and persistence.

Furthermore, the study observed a significant decrease in IFN-γ levels post-vaccination in patients whose symptoms resolved, suggesting that vaccination might aid in clearing the virus that triggers the IFN-γ response.

The Future of Long COVID Treatment

The findings open new avenues for treating long COVID by targeting IFN-γ, potentially offering relief to those suffering from its symptoms.

Moreover, the study suggests that the presence of IFN-γ could help classify long COVID into subtypes, allowing for personalized treatment approaches. This differentiation is crucial, as symptoms and recovery rates vary widely among patients.

As the global community continues to grapple with long COVID and its impacts, understanding the mechanisms behind it is more important than ever.

The University of Cambridge study not only advances our knowledge of long COVID but also prepares us for future challenges by highlighting the importance of vaccination and the need for targeted therapies.

With these insights, the fight against long COVID takes a hopeful step forward, promising better outcomes for patients and a deeper understanding of post-viral conditions.

If you care about COVID, please read studies about vitamin D deficiency linked to severe COVID-19, death, and how diets could help manage post-COVID syndrome.

For more information about COVID, please see recent studies that low-sodium plant-based diets may prevent COVID-19 better, and results showing zinc could help reduce COVID-19 infection risk.

The research findings can be found in Science Advances.

Copyright © 2024 Knowridge Science Report. All rights reserved.